A5060313288- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Venous Thromboembolism Diagnosis and Management
- Lipoproteins and Cardiovascular Health
- Cardiac Valve Diseases and Treatments
- Cardiac Health and Mental Health
- Angiogenesis and VEGF in Cancer
- Heart Failure Treatment and Management
- Chronic Kidney Disease and Diabetes
- Pericarditis and Cardiac Tamponade
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Infective Endocarditis Diagnosis and Management
- Vascular Procedures and Complications
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiovascular Disease and Adiposity
- COVID-19 Clinical Research Studies
- Acute Kidney Injury Research
Rabin Medical Center
2016-2025
Tel Aviv University
2016-2025
The University of Texas Southwestern Medical Center
2019
Southwestern Medical Center
2019
Yan'an Hospital Affiliated To Kunming Medical University
2018
Kunming Medical University
2018
Brigham and Women's Hospital
2015-2017
Harvard University
2015-2017
Thrombolysis in Myocardial Infarction Study Group
2015-2017
Bristol-Myers Squibb (Germany)
2015
Calcification of the thoracic aorta is associated with atherosclerotic risk factors, yet its pathogenesis and clinical implications are not elucidated. The goal present study was to assess whether calcification an increased cardiovascular events death in patients stable angina pectoris.A prospective cohort 361 pectoris (307 men, 54 women; age range, 37 83 years) underwent chest spiral computed tomography were evaluated for aortic calcification. We recorded incidence during a 4.5- 6-year...
To examine the efficacy and safety of ezetimibe added to statin in patients with prior coronary artery bypass graft surgery (CABG) following hospitalization for an acute syndrome (ACS).In IMPROVE-IT trial, post-ACS mean low density lipoprotein cholesterol (LDL-C) 93.8 mg/dL at presentation were randomized simvastatin/ezetimibe or simvastatin/placebo. The primary endpoint was cardiovascular death, major event stroke, median follow-up 6 years. Efficacy endpoints examined by CABG status. Among...
Recent findings suggest that atrial fibrillation is associated with sudden cardiac death (SCD). We examined the incidence, characteristics, and factors SCD in patients fibrillation.SCD was defined as witnessed ≤60 minutes from onset of new symptoms or unwitnessed 1 to 24 hours after being observed alive, without another known cause death. Predictors were using multivariate competing risks models. Over 2.8 years (median), 2349 died (40.5 per 1000 patient-years), which 1668 (71%)...
The extent to which angina is associated with future cardiovascular events in patients coronary artery disease has long been debated.Included were outpatients established who enrolled the REACH registry and followed for 4 years. Angina at baseline was defined as necessitating episodic or permanent antianginal treatment. primary end point composite of death, myocardial infarction, stroke. Secondary points included heart failure, hospitalizations, revascularization. independent association...
To describe the cardiac magnetic resonance (CMR) imaging findings of patients who developed myocarditis following messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination.The present study retrospectively evaluated with clinically adjudicated within 42 days first Pfizer-BNT162b2 mRNA COVID-19 vaccination, between 20 December 2020 and 24 May 2021 underwent CMR. A total 15 out 54 (28%) a CMR were included, 100% males, median age 32 years (interquartile range = 22.5-40). Most...
Abstract Aims In this protocol-predefined substudy of the RHAPSODY trial, primary aim was to assess whether pericardial late gadolinium enhancement (LGE) associated with time pericarditis recurrence. Methods and results a Phase 3 double-blind, placebo-controlled, randomized-withdrawal trial that demonstrated efficacy rilonacept in recurrent (RP). Patients history multiple RP an active recurrence were enrolled had option participate cardiac magnetic resonance (CMR) imaging substudy. CMRs...
Background Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association mortality, perhaps because residual confounding by presence heart failure ( HF ). Methods and Results In ENGAGE AF ‐ TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation‐Thrombolysis Myocardial Infarction 48) trial, clinical outcomes without were examined baseline...
BackgroundRilonacept inhibits the interleukin-1 pathway, and extended treatment in patients with recurrent pericarditis reduced recurrence risk by 98% Phase 3 trial RHAPSODY long-term extension (LTE). SARS-CoV-2 vaccination/infection may trigger recurrence, clinical practice, it is unknown whether to continue rilonacept during infection. This post-hoc analysis of LTE aimed inform management vaccinated against or who contract COVID-19.MethodsAnalysis was conducted from May 2020 June 2022. The...
AimTo evaluate the incidence and prognostic implications of ventricular tachyarrhythmias (VTAs) complicating acute myocardial infarction (MI).
To compare the efficacy and safety of edoxaban vs warfarin in high-risk subgroups. ENGAGE AF-TIMI 48 was a multicenter randomized, double-blind, controlled trial 21,105 patients with atrial fibrillation (AF) within 12 months CHADS2 score >2 randomized to higher-dose regimen (HDER) 60 mg/reduced 30 mg, lower-dose (LDER) 15 or warfarin, followed for 2.8 years (median). The primary outcome this analysis net clinical (NCO), composite stroke/systemic embolism events, major bleeding, death....
Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health-related quality of life. RHAPSODY (rilonacept inhibition interleukin-1 alpha beta for recurrent pericarditis: a pivotal symptomatology outcomes study) evaluated the efficacy safety rilonacept (IL-1α -β cytokine trap) in pericarditis. A secondary analysis these data patient-reported outcome questionnaire score change during trial. Methods Results Participants completed 5 (PRO)...
Background Patients who have had an acute coronary syndrome ( ACS ) are at increased risk of recurrent cardiovascular events; however, paradoxically, high-risk patients may derive the greatest benefit from guideline-recommended therapies often undertreated. The aim our study was to examine management, clinical outcomes, and temporal trends after stratified by Thrombolysis in Myocardial Infarction (TIMI) score for secondary prevention, a recently validated tool that incorporates 9 factors....
Uric acid (UA) is elevated in patients with the metabolic syndrome, and there a possible association coronary events. Its future risk of heart failure (HF) not clear. Our objective was to evaluate between levels UA HF stable artery disease (CAD).Serum associated CAD patients.A retrospective cohort analysis among 2939 participants bezafibrate infarction prevention study, assessing long-term incidence over an 8-year follow-up relation baseline UA.Among high UA, larger proportion men, systolic...